Shorter Chain Triglycerides Are Negatively Associated with Symptom Improvement in Schizophrenia.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101596414 Publication Model: Electronic Cited Medium: Internet ISSN: 2218-273X (Electronic) Linking ISSN: 2218273X NLM ISO Abbreviation: Biomolecules Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, 2011-

Antipsychotic Agents/*adverse effects ; Behavioral Symptoms/*epidemiology ; Biomarkers/*blood ; Lipidomics/*methods ; Schizophrenia/*drug therapy ; Triglycerides/*blood; Adolescent ; Adult ; Behavioral Symptoms/blood ; Behavioral Symptoms/chemically induced ; Behavioral Symptoms/diagnosis ; Female ; Humans ; Inpatients/psychology ; Inpatients/statistics & numerical data ; Male ; Russia/epidemiology ; Schizophrenia/pathology ; Treatment Outcome ; Young Adult

Schizophrenia is a serious mental disorder requiring lifelong treatment. While medications are available that are effective in treating some patients, individual treatment responses can vary, with some patients exhibiting resistance to one or multiple drugs. Currently, little is known about the causes of the difference in treatment response observed among individuals with schizophrenia, and satisfactory markers of poor response are not available for clinical practice. Here, we studied the changes in the levels of 322 blood plasma lipids between two time points assessed in 92 individuals diagnosed with schizophrenia during their inpatient treatment and their association with the extent of symptom improvement. We found 20 triglyceride species increased in individuals with the least improvement in Positive and Negative Syndrome Scale (PANSS) scores, but not in those with the largest reduction in PANSS scores. These triglyceride species were distinct from the rest of the triglyceride species present in blood plasma. They contained a relatively low number of carbons in their fatty acid residues and were relatively low in abundance compared to the principal triglyceride species of blood plasma.

PLoS One. 2019 Mar 20;14(3):e0214141. (PMID: 30893377)
PLoS Biol. 2020 Sep 28;18(9):e3000870. (PMID: 32986697)
Schizophr Bull. 2016 Nov;42(6):1418-1437. (PMID: 27217270)
J Proteome Res. 2015 May 1;14(5):2322-30. (PMID: 25784130)
Sci Rep. 2020 Oct 12;10(1):17028. (PMID: 33046806)
Psychiatry Res. 2019 Feb;272:18-29. (PMID: 30579177)
Schizophr Res. 2015 Feb;161(2-3):506-10. (PMID: 25497441)
NPJ Schizophr. 2020 Jan 7;6(1):1. (PMID: 31911624)
Schizophr Bull. 2013 Mar;39(2):306-18. (PMID: 22207632)
Am J Psychiatry. 1995 May;152(5):698-703. (PMID: 7726309)
J Lipid Res. 2018 Oct;59(10):2001-2017. (PMID: 30115755)
Schizophr Res. 2004 Sep 1;70(1):1-17. (PMID: 15246458)
Dialogues Clin Neurosci. 2018 Mar;20(1):63-73. (PMID: 29946213)
Transl Psychiatry. 2016 Oct 4;6(10):e906. (PMID: 27701405)
Psychiatry Clin Neurosci. 2019 Mar;73(3):100-108. (PMID: 30156046)
Wiley Interdiscip Rev Syst Biol Med. 2020 Jan;12(1):e1466. (PMID: 31646749)
Prog Neuropsychopharmacol Biol Psychiatry. 2020 Jul 13;101:109945. (PMID: 32304808)
Mol Psychiatry. 2021 Apr;26(4):1310-1320. (PMID: 31471576)
Eur Psychiatry. 2009 Sep;24(6):412-24. (PMID: 19682863)
Eur Psychiatry. 2017 Jun;43:44-50. (PMID: 28365467)
Nat Rev Drug Discov. 2005 Jul;4(7):594-610. (PMID: 16052242)
Anal Chem. 2006 Feb 1;78(3):779-87. (PMID: 16448051)
World J Biol Psychiatry. 2020 Jun;21(5):357-367. (PMID: 31161852)
Transl Psychiatry. 2016 Nov 15;6(11):e951. (PMID: 27845774)
Anal Bioanal Chem. 2019 Sep;411(22):5765-5777. (PMID: 31201457)
Transl Psychiatry. 2012 Aug 14;2:e149. (PMID: 22892715)
Psychiatry Res. 2018 Jul;265:174-182. (PMID: 29719272)
J Psychiatr Res. 2013 Mar;47(3):357-62. (PMID: 23207112)
World J Biol Psychiatry. 2016 Sep;17(6):475-9. (PMID: 27088656)
Nat Rev Neurosci. 2007 Oct;8(10):743-54. (PMID: 17882252)
Metabolomics. 2018 Jun 1;14(6):80. (PMID: 30830385)
J Neuropsychiatry Clin Neurosci. 2011 Spring;23(2):215-8. (PMID: 21677254)
BMC Psychiatry. 2018 Dec 4;18(1):376. (PMID: 30509308)
Eur Arch Psychiatry Clin Neurosci. 2020 Feb;270(1):59-70. (PMID: 30604052)
Metabolism. 2019 Jun;95:65-76. (PMID: 30954559)
Schizophr Bull. 1987;13(2):261-76. (PMID: 3616518)
World J Biol Psychiatry. 2020 Jul 17;:1-14. (PMID: 32677491)
J Proteome Res. 2017 Oct 6;16(10):3558-3566. (PMID: 28786289)
Anal Bioanal Chem. 2016 Sep;408(23):6497-507. (PMID: 27457104)
Diabetologia. 2013 Oct;56(10):2266-74. (PMID: 23824212)
Psychiatry Res. 2012 Aug 15;198(3):347-52. (PMID: 22513041)
Transl Psychiatry. 2019 Jan 17;9(1):19. (PMID: 30655505)
J Affect Disord. 2017 Apr 15;213:35-43. (PMID: 28189963)
Dialogues Clin Neurosci. 2018 Mar;20(1):47-52. (PMID: 29946211)
Curr Neuropharmacol. 2019;17(9):852-860. (PMID: 30819084)
J Clin Invest. 2011 Apr;121(4):1402-11. (PMID: 21403394)
Schizophr Bull. 2015 May;41(3):559-73. (PMID: 25759473)
J Clin Psychiatry. 2012 Jul;73(7):1025-33. (PMID: 22901352)
Neuron. 2016 Apr 6;90(1):11-25. (PMID: 27054615)

19-74-00151 Russian Science Foundation

Keywords: PANSS; lipid; lipidomics; mass spectrometry; schizophrenia; triglyceride

0 (Antipsychotic Agents)
0 (Biomarkers)
0 (Triglycerides)

Date Created: 20210602 Date Completed: 20211005 Latest Revision: 20211005

20250114

PMC8151512

10.3390/biom11050720

34064997